A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax in combination with azacitidine works to treat AML in adult participants in Colombia. Venetoclax in combination with azacytidine is approved to treat Acute myeloid leukemia (AML). All study participants will receive venetoclax in combination with azacitidine as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML will be enrolled. Around 70 participants will be enrolled in the study in Colombia. Participants will receive venetoclax tablets to be taken by mouth in combination with azacitidine given by subcutaneous (SC) or intravenous (IV) injection according to the approved local label. The duration of the study is approximately 36 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowo rozpoznana białaczka ostra potwierdzzona badaniem histologicznym
- •Pacjent wcześniej nie otrzymywał leczenia białaczki
- •Pacjent w wieku 75 lat lub starszy, albo wiek 18-74 lata z chorobami towarzyszącymi uniemożliwiającymi intensywną chemioterapię
- •Pacjent rozpoczął leczenie venetoklaskiem i azacytydyną zgodnie z lokalną etykietą leku w Kolumbii
- •Pacjent nie ukończył jeszcze pierwszego cyklu leczenia (28 dni)
✗ Disqualifies
- •Uczestniczenie w innym eksperymentalnym badaniu klinicznym w ciągu ostatnich 30 dni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 26, 2026
- Sex
- No restrictions
Locations (8)
Hospital Pablo Tobon Uribe /ID# 248569
Medellín, Colombia
Hospital Alma Mater de Antioquia /ID# 248562
Medellin, Colombia
Sociedad de Oncologia y Hematologia del Cesar /ID# 248615
Valledupar, Colombia
Coorp Hosp Juan Ciudad Sede Hospital Universitario Mayor Mederi /ID# 248570
Bogota DC, Colombia
Fundacion Santa Fe De Bogota /ID# 248563
Bogota, Colombia
Clinica del Country /ID# 248430
Bogota, Colombia
FOSCAL International /ID# 287252
Floridablanca, Colombia
Fundacion Valle Del Lili /ID# 248294
Cali, Colombia
Trial contact
Angela Duarte
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/27/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.